Introduction
The semaphorins are a family of proteins involved in cell migration, and so are implicated in nerve regeneration (Pasterkamp et al., 1998) , tumorigenesis (Christensen et al., 1998) , cardiovascular morphogenesis (Behar et al., 1996; Miao et al., 1999) and immune response (Hall et al., 1996) . The class 3 semaphorins (SEMA3s) are secreted proteins consisting of seven members, SEMA3A through -3G. Neuropilins (NRP1 and NRP2) and plexins form functional semaphorin receptors that transfer semaphorin signaling into the cells (Kolodkin et al., 1993; He and Tessier-Lavigne, 1997) . SEMA3E is the only exception to the above scheme in that it directly binds to a plexin (Gu et al., 2005 ). An isoform of vascular endothelial growth factor (VEGF), VEGF 165 , is a product of alternative mRNA splicing and also binds to NRPs. The VEGF 165 -NRP complex then binds to VEGFR2 and transmits its signal (Soker et al., 1996 (Soker et al., , 1998 . Therefore, the NRPs are a component of both the SEMA3-NRP-plexin complexes and the VEGF 165 -NRP-VEGFR2 complexes, and are located at the crossroads of SEMA3 and VEGF signaling. SEMA3s and VEGF 165 inhibit each other by competing for available molecules of NRP (Mac Gabhann and Popel, 2006) . SEMA3B has a tumor suppressor activity. Addition of SEMA3B protein to the medium or introduction of SEMA3B expression plasmid into the cells induces apoptosis and decreases colony-forming activity in NCI-H1299 cells (Sekido et al., 1996; Tomizawa et al., 2001 ). SEMA3B expression is induced by p53 mediated by a p53 responsive element located in the promoter (Ochi et al., 2002) . SEMA3B expression is frequently suppressed by the methylation of the promoter in lung cancers (Tomizawa et al., 2001) . The SEMA3B gene is located at 3p21.3 where chromosomal deletions have frequently been observed in lung cancers (Sekido et al., 1996; Tomizawa et al., 2001) . These data suggest that SEMA3B may have a tumor suppressor activity that is attributable to the competitive inhibition of VEGF 165 working as an autocrine survival factor in some cancer cells (Castro-Rivera et al., 2004) .
Recent studies on two other members of the SEMA3 family have demonstrated complexity in their signaling pathways. SEMA3A inhibits VEGF activity by mechanisms that are both dependent on and independent of the competition for receptor binding (Guttmann-Raviv et al., 2006) . b-catenin/T-cell factor (TCF) signaling has been implicated in the growth inhibitory effects of SEMA3F (Nasarre et al., 2005) . These findings suggest that, in addition to the competition with VEGF 165 , SEMA3B may employ an as yet unidentified mechanism for its tumor suppressor activity.
In this study, we have investigated whether SEMA3B activity is mediated by a mechanism other than competition with VEGF 165 . Some tumor suppressors function by inducing the expression of their effector genes (Yu et al., 2001; Barz et al., 2006; Chow et al., 2006; Feng et al., 2006) . We hypothesized that SEMA3B might be such a tumor suppressor. To test this hypothesis, we employed microarray technology and screened for those genes with increased expression following SEMA3B transfection. We then investigated whether and by what mechanism the identified gene, insulin-like growth factor-binding protein-6 (IGFBP-6), acted as an effector of SEMA3B.
Results

Establishment of stable SEMA3B transfectants
Cell lines (stSEMA3B and stSEMA3B-FLAG) that stably express the native form of SEMA3B or a FLAG-tagged SEMA3B were established by introducing their expression plasmids into NCI-H1299 cells that do not express SEMA3B. This established an experimental system where SEMA3B expressed from the plasmid was secreted and acted on the cells in an autocrine manner. As SEMA3B function may be posttranslationally modified, this system was considered more suitable for investigating SEMA3B function than what employs recombinant proteins expressed in prokaryotes. SEMA3B was detected both in the conditioned medium (CM; Figure 1a ) and in the cytoplasm (cell lysate, CL; Figure 1b) . Expression was not observed in the cell line (stpcDNA) that was established by transfecting an empty plasmid.
Identification of IGFBP-6
We employed a microarray to search for mRNAs that were more highly expressed in stSEMA3B than in stpcDNA in an attempt to find a gene that is an effector of SEMA3B (Figure 2a , also see Supplementary information). Reverse transcription PCR (RT-PCR) was performed on several growth-related genes to confirm the microarray data (Figure 2b ). Among the cell growth-related genes studied, IGFBP-6 showed the greatest increase. As expected, IGFBP-6 protein was increased in CM of stSEMA3B, as was in CM of trSEMA3B, stSEMA3B-FLAG and trSEMA3B-FLAG (Figure 2c ). IGFBP-6 has been shown to suppress the growth of cancer cells (Sueoka et al., 2000; Leng et al., 2001; Koike et al., 2005) and thus may be an effector of tumor suppressor activity for SEMA3B. Next, we semiquantified the expression levels of SEMA3B and IGFBP-6 in lung cancer cell lines (Figure 2d ). The expression of IGFBP-6 positively correlated with that of SEMA3B and was lower than that of normal lung tissue. These observations were consistent with the hypothesis that IGFBP-6 is an effector of SEMA3B and so we decided to further investigate the functions of IGFBP-6. Suppression of colony formation by IGFBP-6 IGFBP-6 binds to and sequesters insulin-like growth factor II (IGF-II) (Bach et al., 1994) . IGF-II often acts as an autocrine growth factor stimulating the growth of some cancer cells, whereas IGFBP-6 suppresses their growth (Kato et al., 1995) . Therefore, IGFBP-6 acts as a tumor suppressor for such cancer cells. In addition to this IGF-II-dependent mechanism, IGFBP-6 may act by an IGF-II-independent mechanism to exert its tumor suppressor activity. This mechanism is as yet vaguely understood (Grellier et al., 1998; Sueoka et al., 2000) . The effect of IGFBP-6 on the growth of NCI-H1299 cells was studied by measuring colony formation on the dish surface and in soft agar (Figures 3a and b) . In both assays, the introduction of an IGFBP-6 expression plasmid significantly reduced the number of colonies, demonstrating that IGFBP-6 exerted a tumor suppressor activity on NCI-H1299 cells.
Inhibition of IGFBP-6 suppressed SEMA3B effects Results obtained so far suggest that SEMA3B exerts a tumor suppressor activity by inducing the expression of IGFBP-6 as IGFBP-6 is an immediate cause of the activity. To confirm this, we investigated whether the inhibition of IGFBP-6 could abrogate the tumor suppressor activity of SEMA3B.
First, we used small interfering RNA (siRNA) to inhibit IGFBP-6. RT-PCR and western blot analyses showed that 10 nM of IGFBP-6 siRNA efficiently inhibited the expression of IGFBP-6 ( Figure 4a ); so this concentration was used. Introduction of SEMA3B cDNA into NCI-H1299 cells increased the sub-G0/G1 population, reflecting the tumor suppressor activity of SEMA3B (Figure 4b ). Transfection of IGFBP-6 siRNA canceled this effect (Figure 4b(iii) ), whereas that of scrambled siRNA did not (Figure 4b ). Transfection of IGFBP-6 siRNA but not scrambled siRNA also abrogated the growth inhibition by SEMA3B (Figure 4c ). Second, we used IGF-II to inhibit IGFBP-6, as the amount of IGF-II higher than that of IGFBP-6 is able to sequester the growth suppressor activity of IGFBP-6 (Bach et al., 1995) . In the presence of 50 ng/ml of human IGF-II, the effect of IGFBP-6 was partially abrogated (Figure 4d ). These results demonstrate that Interaction of SEMA3B and b-catenin/TCF signaling b-catenin is a key component of Wnt/TCF signaling. An accumulation of b-catenin in the cytoplasm activates TCFs and modifies the expression of downstream genes. Excessive activity in the b-catenin/TCF pathway is often observed in cancer cells (Nelson and Nusse, 2004; Clevers, 2006) . In NCI-H1299 cells, TCF activity is induced by introducing b-catenin cDNA (Usami et al., 2003) . The IGFBP-6 promoter has two copies of TCFbinding motifs, and b-catenin suppresses the expression of IGFBP-6 through these motifs (Denys et al., 2004) . These results suggest that, in NCI-H1299 cells, b-catenin may antagonize the tumor suppressor activity of SEMA3B by inhibiting the expression of IGFBP-6. To confirm this, we introduced b-catenin cDNA into stSEMA3B to establish stSEMA3B-b-catenin and investigated its effect. The introduction of b-catenin cDNA reduced the expression of IGFBP-6, which had been increased by the introduction of SEMA3B cDNA (Figure 5a) . Moreover, the growth-suppressing activity of SEMA3B was partially abrogated (Figure 5b ). These observations are consistent with the inference that b-catenin may antagonize SEMA3B, and indicate that SEMA3B signaling and b-catenin/TCF signaling converge at IGFBP-6 to affect the growth of NCI-H1299 cells.
Discussion
The aim of our study was to find out the as yet unidentified mechanism for the growth inhibition of lung cancer cells by SEMA3B. We have demonstrated that SEMA3B exerted its growth inhibitory effect through the induction of IGFBP-6 expression, and the effect was antagonized by b-catenin.
SEMA3B is an extracellular factor that binds to its receptor, transmits the signal into the cell and affects the cell growth. Signaling that is mediated by a membrane receptor often induces activation or inactivation of a specific transcription factor that changes the transcription of a variety of genes. The transcribed gene in turn exerts its function on cell growth. We speculate that a similar mechanism is at work for SEMA3B because SEMA3B increases the amount of IGFBP-6 mRNA. Whatever the mechanism, the identification of the effector would have been a tremendous challenge without microarray technology. We focused only on growth-related genes to narrow the number of candidates to identify the effector. Similar approaches are found in the literature where the researchers employed a microarray and showed that peroxisome proliferatoractivated receptor g is a Zac target gene mediating Zac antiproliferation, and that heat shock protein 70 induced by the inhibitor of growth 1 sensitized cells to tumor necrosis factor-a receptor-mediated apoptosis (Barz et al., 2006; Feng et al., 2006) . With an enrichment of functional information on individual genes, the strategy taken in this study and others will become much easier and more promising.
Members of the IGFBP family act on cell migration and growth in both IGF-dependent and IGF-independent mechanisms (Firth and Baxter, 2002) . IGFBP-6 is unique among the family members as it provides a 20-to 100-fold higher affinity to IGF-II than to IGF-I (Martin et al., 1990; Bach, 1999) . The affinity is not so much differentiated in other members of IGFBPs. IGFBP-6 sequesters IGF-II, and thus inhibits growth in lung SEMA3B exerts tumor suppressor effect through IGFBP-6 N Koyama et al cancer (Sueoka et al., 2000) , colorectal cancer (Leng et al., 2001) , prostate cancer (Koike et al., 2005) , neuroblastoma (Grellier et al., 1998) and rhabdomyosarcoma (Gallicchio et al., 2001) , whereas its expression is lower in malignant or metastatic tumors than in benign or non-metastatic tumors (Scholl et al., 2000; Yao et al., 2002) . Moreover, the p53 tumor suppressor increases IGFBP-6 expression (Kannan et al., 2001) . These results indicate that IGFBP-6 is a tumor suppressor for a variety of cancers. In our experiment, inhibition of IGFBP-6 by siRNA abolished the effect of SEMA3B on NCI-H1299 cells, indicating that the The effect on cell proliferation investigated by the cell growth assay. Cell growth suppressed by the introduction of SEMA3B is restored by IGFBP-6 siRNA. (d) The effect on colony formation. Numbers of colonies formed on the dish surface or in soft agar after the transfection of either the SEMA3B expression vector (SEMA3B-pcDNA3.1/Zeo(À)) or an empty vector (pcDNA3.1/Zeo(À)). The medium contained 400 mg/ml of Zeocin together with either 0 or 50 ng/ml of human IGF-II. Experiments were done in triplicates. Error bars indicate standard deviations. IGF-II, insulin-like growth factor II; IGFBP-6, insulin-like growth factor-binding protein-6; RT-PCR, reverse transcription PCR; siRNA, small interfering RNA.
SEMA3B exerts tumor suppressor effect through IGFBP-6 N Koyama et al growth inhibitory effect of SEMA3B is mediated by IGFBP-6 and links the effects of these two tumor suppressors.
Pathways that transmit growth-related signals often converge on key molecules to antithetically affect their functions. We showed that IGFBP-6 is one of such key molecules where the signaling from SEMA3B and b-catenin converges. Semaphorin increases the expression of phosphatase protein homolog to tensin (PTEN) and activates glycogen synthase kinase-3b, resulting in the inhibition of integrin-mediated adhesion to the extracellular matrix (Tran et al., 2007) . These results suggest that semaphorin signaling and b-catenin/TCF signaling may also converge at other points, which we have shown in this study.
Carcinogenesis requires both the activation and the inactivation of multiple signaling pathways, leading to the concept of multistep carcinogenesis. Further study into the interrelationship of SEMA3B signaling with other signaling pathways will contribute to our overall understanding of cancers.
Materials and methods
Cell lines
Lung cancer cell lines were obtained as follows. NCI-H1299 (large cell neuroendocrine carcinoma) was purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). PC-7 and PC-9 (adenocarcinomas) were purchased from IBL (Takasaki, Japan). RERF-LC-Ad1, RERF-LCAd2, RERF-LC-MS and PC-3 (adenosquamous carcinomas), as well as RERF-LC Sq-1 (squamous cell carcinomas) were purchased from the Japanese Collection of Research Bioresources (Tokyo, Japan). RERF-LC-KJ, LC2/ad and PC-14 (adenocarcinomas), and RERF-LC-A1 (squamous cell carcinomas) were purchased from the Riken Bioresource Center (Tsukuba, Japan). SBC3 and SBC5 (small cell carcinomas) were purchased from the Health Science Research Resources Bank (Osaka, Japan). A549 (adenocarcinoma), LK79 and LK2 (squamous cell carcinomas) were obtained from the Cell Resource Center for Biomedical Research (Tohoku University, Japan). Cells were grown in RPMI medium 1640 (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (CELLect GOLD; MP Biomedicals, Eschwege, Germany).
Plasmid construction and transfection
A plasmid, SEMA3B-pcDNA3.1/Zeo(À), that expresses wildtype SEMA3B protein was constructed by inserting human SEMA3B full-length cDNA into pcDNA3.1/Zeo(À) (Invitrogen, Carlsbad, CA, USA). A plasmid, SEMA3B-pCMVTag2A, that expresses N-terminal FLAG-tagged SEMA3B protein was constructed by inserting human SEMA3B fulllength cDNA into pCMV-Tag2A (Stratagene, La Jolla, CA, USA). A plasmid, IGFBP-6-pcDNA3.1/Zeo(À), that expresses IGFBP-6 protein was constructed by inserting human IGFBP-6 full-length cDNA into pcDNA3.1/Zeo(À). A plasmid, b-catenin-pcDNA3.1( þ ), that expresses b-catenin protein was constructed by inserting human b-catenin full-length cDNA into pcDNA3.1( þ ) (Invitrogen). These plasmids and the three appropriate negative control plasmids, pcDNA3. 1/Zeo(À), pCMV-Tag2A and pcDNA3.1( þ ), were transfected into NCI-H1299 cells using FuGENE 6 transfection reagent (Roche, Basel, Switzerland) according to the manufacturer's instructions. In brief, a plasmid (1 mg) and FuGENE 6 (3 ml) were complexed in 100 ml Opti-MEM (Invitrogen) for 15 min. The complex was added to 3 Â 10 5 NCI-H1299 cells seeded in a 35-mm dish and the cells were incubated for 48 h (transient transfectants). To establish the stable transfectants, transient transfectants were incubated in the medium containing 400 mg/ ml Zeocin (Invitrogen) or 1 mg/ml Geneticin (Invitrogen) for 14 days. The drug-resistant colonies were cloned, and the clones were expanded. The names of the plasmids transfected and the names of the stable transfectants are paired below and are separated by commas: SEMA3B-pcDNA3.1/Zeo(À), stSEMA3B; SEMA3B-pCMV-Tag2A, stSEMA3B-FLAG; SEMA3B-pcDNA3.1/Zeo(À) and b-catenin-pcDNA3.1( þ ), stSEMA3B-b-catenin; pcDNA3.1/Zeo(À), stpcDNA; pCMVTag2A, stpCMV-FLAG. The names of the plasmids transfected and the names of the transient transfectants are SEMA3B-pcDNA3.1/Zeo(À), trSEMA3B; SEMA3B-pCMVTag2A, trSEMA3B-FLAG; SEMA3B-pcDNA3.1/Zeo(À) and b-catenin-pcDNA3.1( þ ), trSEMA3B-b-catenin; pcDNA3.1/ Zeo(À), trpcDNA; pCMV-Tag2A, trpCMV-FLAG. Western blot analysis Cells (1 Â 10 7 ) were plated in a 100-mm dish and incubated in 10 ml RPMI-1640 for 24 h. Cell lysate was prepared using mammalian cell lysis/extraction reagent (Sigma). Both the cell lysate and the cryoconcentrated conditioned medium were subjected to western blot analysis. Samples were dissolved in LDS sample buffer (Invitrogen), heated at 99 1C for 5 min, electrophoresed in NuPAGE 4-12% bis-Tris gel (Invitrogen) and transferred to polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA). The membrane was immersed in 5% skim milk, 0.1% Tween 20 and dissolved in Tris-buffered saline to block the nonspecific binding. The membranes were incubated overnight at 4 1C with a primary antibody that included goat anti-human SEMA3B polyclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), mouse anti-human IGFBP-6 monoclonal antibody (R & D Systems, Minneapolis, MN, USA) or mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) monoclonal antibody (Chemicon International Inc., Billerica, CA, USA). The membranes were then incubated for 1 h at 25 1C with a secondary antibody that included horseradish peroxidaseconjugated anti-goat, anti-rabbit or anti-mouse IgG (Santa Cruz Biotechnology). The specific signals were visualized by ECL plus (GE Healthcare Bio-Sciences, Piscataway, NJ, USA).
Immunoprecipitation
Cells were harvested and sonicated in lysis buffer that contained Tris-HCl (50 mM), NaCl (150 mM), EDTA (0.1 mM), 1% Triton-X, 1% NP-40 and Complete Protease Inhibitor Cocktail Tablets (Roche). The FLAG-tagged recombinant protein was captured to the EZview Red ANTI-FLAG M2 Affinity Gel (Sigma) for 24 h at 4 1C. Bound proteins were eluted in an extraction buffer by boiling the gel at 100 1C for 5 min, electrophoresed in an SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane. The protein was detected as described in the section 'Western blot analysis' except that a mouse monoclonal ANTI-FLAG M2 (Sigma) was used as the primary antibody.
Microarray analysis stSEMA3B was used as the reference cell line and stpcDNA was used as the control cell line. Total RNA was extracted from the cells by use of the Trizol reagent (Invitrogen). DNA from the RNA sample was completely removed by digesting with RQ1 RNase-free DNase (Promega, Madison, WI, USA), followed by phenol-chloroform extraction. Microarray analysis was performed using the Amersham CodeLink Bioarray Systems (GE Healthcare Bio-Sciences).
RT-PCR IGFBP-6, PTEN and discoidin, CUB and the LCCL domain containing 2 (DCBLD2), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) and vesicle-associated membrane protein-associated protein A (VAPA) were used as probe genes and GAPDH as a control. Total RNA was reverse-transcribed using the SuperScript III First-Strand Synthesis System (Invitrogen). One microgram of cDNA was subjected to PCR (1 cycle of 0 -CCTCAACGACCACTTTGTCA-3 0 (forward) and 5 0 -TTACTCCTTGGAGGCCATGT-3 0 (reverse). Each mRNA was quantified using its amplification data and then normalized using the amount of GAPDH mRNA.
Colony formation on the dish surface Cells transfected with a plasmid and incubated for 48 h (see 'Plasmid construction and transfection' above) were replated into a 10-cm dish and cultured for 14 days in RPMI-1640 containing 10% fetal bovine serum and 400 mg/ml Zeocin. In the experiment investigating the effects of IGF-II on the growth inhibition through IGFBP-6, the medium also contained 0 or 50 ng/ml of human IGF-II (Strathmann Biotech Gmbh, Hamburg, Germany).
Colony formation in soft agar NCI-H1299 cells (15 000 cells) transfected with either pcDNA3.1/Zeo(À) or SEMA3B-pcDNA3.1/Zeo(À) and incubated for 48 h (see 'Plasmid construction and transfection' above) were suspended in medium (RPMI-1640, 10% fetal bovine serum, 400 mg/ml Zeocin and 0 or 50 ng/ml of human IGF-II) containing 0.33% melted agar. The suspension was solidified on a presolidified medium containing 0.5% agar. The same medium was placed on top of the double agar layer and was renewed every 2 days. The cultures were incubated for 14 days and then the numbers of colonies were counted.
Transfection of small interfering RNA The siRNAs for IGFBP-6 were sense, 5 0 -CCCGCCCACAG GAUGUGAACC-3 0 and antisense, 5 0 -UUCACAUCCU GUGGGCGGGCA-3 0 . These sequences were rearranged and used to design negative control siRNAs that were sense, 5 0 -CGCAUGCGGACUGCCAACACC-3 0 and antisense, 5 0 -UGUUGGCAGUCCGCAUGCGCA-3 0 . Different concentrations of siRNA were transfected into stSEMA3B by Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Total RNA or cellular protein was extracted 48 or 72 h after transfection, respectively.
Flow cytometry analysis
Seventy-two hours after the siRNA transfection, cells were harvested, fixed in 70% ethanol and suspended in phosphate-SEMA3B exerts tumor suppressor effect through IGFBP-6 N Koyama et al buffered saline containing 20 mg/ml Ribonulease A (Sigma), 50 mg/ml propidium iodide, 0.1% sodium citrate and 0.3% NP-40. Flow cytometry was performed using the FACSCalibur equipped with CELLQUEST software (Becton Dickinson, Franklin Lakes, NJ, USA).
Cell growth assay
One thousand cells per well of stpcDNA, stSEMA3B or stSEMA3B-b-catenin were seeded into 96-well dishes containing 100 ml of RPMI-1640 with 2% fetal bovine serum (day 0). On days 1, 2 and 3, 10 ml of Cell Counting Kit-8 reagent (DOJINDO, Kumamoto, Japan) was added to each well. Cells were then incubated for 3 h, and the absorbance at 450 nm/ 620 nm was measured. Five samples were analysed for each cell group. For the assay treated with siRNA, IGFBP-6 or scrambled siRNA was transfected into 3000 cells per well of stpcDNA or stSEMA3B on day 1. The medium was changed to remove the siRNAs 6 h after transfection, and the cells were incubated for 72 h. On day 4, the absorbance was measured.
